|
|
Volumn 101, Issue 24, 2009, Pages 1662-1664
|
|
Costly cancer drugs trigger proposals to modify clinical trial design.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
MONOCLONAL ANTIBODY;
CLINICAL TRIAL;
COST BENEFIT ANALYSIS;
COST OF ILLNESS;
DISEASE FREE SURVIVAL;
DRUG COST;
ECONOMICS;
FINANCIAL MANAGEMENT;
HEALTH CARE ORGANIZATION;
HUMAN;
METHODOLOGY;
NOTE;
TREATMENT FAILURE;
UNITED STATES;
ANGIOGENESIS INHIBITORS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS AS TOPIC;
COST OF ILLNESS;
COST-BENEFIT ANALYSIS;
DISEASE-FREE SURVIVAL;
DRUG COSTS;
HEALTH CARE RATIONING;
HUMANS;
RESEARCH DESIGN;
RESEARCH SUPPORT AS TOPIC;
TREATMENT FAILURE;
UNITED STATES;
|
|
EID: 73449111310
PISSN: None
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djp460 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|
